Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients

Journal of Investigative Medicine

Volumn 59, Issue 7, 2011, Pages 1096-1103

  McDaniel, D Olga ^a,b   Thurber, Tonya ^a   Lewis Traylor, Angela ^b   Berry, Crystal ^a   Barber, William Henry ^a,b   Zhou, Xinchun ^c   Bigler, Steven ^a,c   Vance, Ralph ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b Departments of Surgery   (United States)

^c Departments of Pathology   (United States)

Author keywords

African Americans; Breast cancer; Caucasians; CYP 3A4 genotypes; Receptors

Indexed keywords

CYTOCHROME P450 3A4; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST TUMOR; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; ALLELES; BIOPSY; BREAST NEOPLASMS; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MASTECTOMY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; STEROIDS;

EID: 84863025210     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182277e3b     Document Type: Article

References (38)

1. Worsham MJ, Abrams J, Raju U, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multi-ethnic, primary health care population. Breast J. 2007;13:115-121. (Pubitemid 46280598)
2. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA. 1995;92:3650-3657.
3. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17-35. (Pubitemid 23269068)
4. Kristensen VN, BLrresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutation Res. 2000;462:323-333. (Pubitemid 30190238)
5. Modugno F, Knoll C, Kanbour-Shakir A, et al. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003;82:191-197. (Pubitemid 37521975)
6. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17A-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology. 2003;144:3382-3398. (Pubitemid 36904414)
7. Yu A-M, Fukamachi K, Krausz KW, et al. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology. 2005;146:2911-2919. (Pubitemid 41002798)
8. Williams ET, Leyk M, Wrighton ST, et al. Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Experimental Ther. 2004;311:728-735. (Pubitemid 39391561)
9. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115-124. (Pubitemid 41174580)
10. Rebbeck TR, Troxel AB, Walker AH, et al. Pairwise combination of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev. 2007;16:444-450. (Pubitemid 46548647)
11. Telang NT, Suto A, Wong GY, et al. Induction by estrogen metabolite 16-alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst. 1992;84:634-638.
12. Hesselink DA, vab Schaik HN, van der Heiden IP, et al. Genetic polymorphisms of the CYP 3A4, CYP 3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254. (Pubitemid 37083100)
13. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effect of chemotherapy. Clin Cancer Res. 2009;15:4806-4814.
14. Wang J. CYP 3A4 polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diag. 2009;9:383-390.
15. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP 3A4. Clin Pharmacol Ther. 1999;66:288-294. (Pubitemid 29451761)
16. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229. (Pubitemid 28407089)
17. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901-905. (Pubitemid 29508726)
18. Kittles RA, Chen W, Panguluri RK, et al. CYP3A4-V and prostate cancer in African Americans: casual or confounding association because of population stratification. Hum Genet. 2002;110: 553-560. (Pubitemid 36075004)
19. Tayeb MT, Clark C, Haites NE, et al. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Canc. 2003;88:928-932. (Pubitemid 36520881)
20. Galant C, Gala JL, Berg VD, et al. Immunolocalization of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumor differentiation and steroid receptors. Pharmacol Toxicol. 2001;88:142-146.
21. Iscan M, Klaavuniemi T, Coban T, et al. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat. 2001;70:47-54. (Pubitemid 33105102)
22. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1998;95:13176-13181. (Pubitemid 28509544)
23. Kajinami K, Brousseau ME, Ordovas JM, et al. Cyp3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol. 2004;93:104-107. (Pubitemid 38022047)
24. Zhou X, Barber WH, Moore CK et al. Frequency distribution of cytochrome P450 3A4 gene polymorphism in ethnic populations and in transplant recipients. Res Commun Mol Pathol Pharmacol. 2006;119:89-104. (Pubitemid 47579203)
25. Miller SO, Ewing GP, Howard C, et al. Incorporating cytochrome P450 3A4 genotype expression and FT-IR/Raman spectroscopy data as means of identification of breast tumors. Biomed Sci Instrum. 2003;39:24-29. (Pubitemid 36433398)
26. McDaniel DO, Barber WH, Nguyan C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transpl Immunol. 2003;11:107-119. (Pubitemid 36553290)
27. McDaniel DO, Ihedigbo CE, May W, et al. Are cytokine gene polymorphisms associated with hypertension? An African American cohort study. J Public Admin Manage. 2008;12:18-42.
28. Hashimoto H, Toide K, Kitamura R, et al. Gene structure of CYP 3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem. 1993;218:585-595. (Pubitemid 24003776)
29. Welcsh PL, King M-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Mol Genet. 2001;10:705-713. (Pubitemid 32331579)
30. Huang Z, Fasco MJ, Figge HL, et al. Expression of cytochrome P450 in human breast tissue and tumors. Drug Metab Dispos. 1996;24:899-905. (Pubitemid 26274749)
31. Wen W, Ren Z, Shu XO, et al. Expression of cytochrome P450 1B1 and catechol-o-methyltransferase in breast tissue and their associations with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:917-920. (Pubitemid 46910092)
32. Spurdle AB, Goodwin B, Hodgson E, et al. The CYP3A4 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355-366. (Pubitemid 34816415)
33. Kadlubar FF, Berkowitz GS, Delongchamp RR, et al. The CYP3A4 1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:327-331. (Pubitemid 36427993)
34. Keshava C, McCanlies EC, Weston A. CYP 3A4 polymorphismsVpotential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004;160:825-841. (Pubitemid 39434767)
35. Marchand LL, Donlon T, Kolonel LN, et al. Estrogen metabolism related and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2005;14:1998-2003. (Pubitemid 41161214)
36. Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetaxel by CYP 3A4 mRNA expression in breast cancer tissues. Int J Cancer. 2002;97:129-132.
37. Miyoshi Y, Taguchi T, Kim SJ, et al. Prediction of response to docetaxel by immunohistochemical analysis of CYP 3A4 expression in human breast cancers. Breast Cancer. 2005;12:11-15.
38. Nagaoka R, Iwasaki T, Rokutanda N, et al. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine. 2006;30:261-268. (Pubitemid 47010961)